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Four groups were studied: Group I = potato with 
mgkg intravenous aspirin (n = 61, Group II = pretrea 
ve dogs, p&sting in one; in Group MI, 
in all five dogs, persist@ in four; in Group IV 
The frequency of persistent reflow in Group III was 
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bolytic therapy in patients with acute m 
Recanalization of the occluded coronary artery with throm- 
bolytic therapy may reduce the mortality rate in patients 
with acute myocardial infarction (I-41, but the effect is most 
pronounced if reflow is obtained early and is persistent. 
However, with the currently used agents and infusion pro- 
tocols, coronary artery reflow is often delayed (5-7) and 
reocclusion isrelatively frequent (C-12). consequently, dif- 
ferent therapeutic approaches have been i vestigated to
accelerate r canalization a d prevent reocclusion. These 
include the use of anticoagulants (13,141 and potent anti- 
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artery thrombosis w 
(25) that has many 
weight intravenously) and additional doses as required. The 
dogs were intubated and placed on a respirator with a tidal 
volume of 10 to 15 ml/kg. rocaiaamide (1.5 g i~tram~scM- 
larly) and lidocaine (0. I mglkg in iutraveno~s~y~ were 
The left carotid artery 
ough an incision in the neck and canmdated 
- 1 modeled Amplatz coronary angiographic 
catheter. Thoracotomy was performed through the left fifth 
intercostal space, with cannrulation of the left internal mam- 
mary artery for continuous blood pressure recording. The 
pericardium was opened and suspended to create a pericar- 
site. Tbrombj~ (0. I 
coronary artery 
bolus injection of 17 mg/ 
; Group II with intravenou 
rgatroban (~e~efltecb~ over 
10 mg ~rotamiue sulfate. Tbe t 
carried out with a constant rate 
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Fii 1. Schematic representation of the time course of the exper- 
iments. The surgical procedure for the production of a whole blood 
clot with superimposed endothelial cell damage and high grade 
stenosis was carried out over approximately 90 min. The clot was 
aged for 30 min before bolus administration of aspirin or 7E3-F(ab’12 
(open trlangte) or the start ofthe Argatroban infusion (-1. Ten 
minutes later a bolus injection of 0.45 mglkg of recombinant tissue- 
type plasminogen activator (rt-PA) (closed triangles) was given and 
repeated at I5 min intervals until reperfusion occurred or until a 
maximum of four bolus injections. The coronary patency status was 
monitored continuously for 120 min after the first rt-PA bolus 
injection. Blood samples were taken at baseline, before the admin- 
istration of study drug (aspirin, 7E3-F[ab’]2 or Argatroban), 20 min 
after the first r-t-PA injection and toward the end of the experi 
0 = protamine sulfate injection (in 7E3-F(ab’)2 group only). 
mg/kg at 15 min intervals until recanalization f the throm- 
bosed coronary artery was achieved or up to a maximum of
four bolus injections. A coronary angiogram was obtained 
every 15 min to monitor occlusion and when the flow probe 
showed evidence of reflow. Reflow was monitored both 
angiographically nd by flow probe for at least 2 h after the 
initial angiographic confirmation f stable coronary occlu- 
sion. 
The reflow time was recorded as the time from the first 
rt-PA bolus injection until recanalization upas documented 
by the return of blood flow in the artery to 225% of that 
before thrombus formation and confirmed by complete 
angiographic f lling of the apex with rapid clearance of the 
dye in four or fewer heartbeats. After recanalization was 
obtained, blood flow was monitored for evidence of reocclu- 
sion, defined as <25% baseline flow, with the final confir- 
mation obtained by angiography showing dye clearance in
more than five cycles. The reocclusion time was defined as 
the interval between documented reflow and reocclusion. 
Frequently, cyclic reflow occurred, interspersed with peri- 
ods of reocclusion. 
The coronary artery patency status was categorized as 
follows: 1) persistent occlusion = no reflow; 2) reocclusion 
after eflow = reocclusion persisting for ~$0 min before the 
end of the experiment, after initial reflow; 3) cyclic reflow = 
alternating reocclusion and recanalization after initial reflow; 
and 41 persistent patency = persistent flow without reocclu- 
sion after initial reflow. The studies with experimental ani- 
mals were carried out in conformance with the Position of 
the American Heart Association on Research Animal Use, 
adopted November 1 I, 1984. 
ostasis assays. Blood sam 
before the administration of as 
F(ab’)2, 20 min after the first rt 
toward the end of the experiment. 
mination of the activated partial thrombop~ast~~ time, throm- 
bin time and glycoprotein IIb/IIIa receptor saturation were 
drawn into a 0.01 M citrate solution. 
The binding of iodine-l25-7E3 to 
by incubating 0.2 ml titrated platelet- 
x lo* platelets/ml with 20 ~1 of iodine- 
al co~ce~t~at 
be a near s 
duplicate 0.1 ml aliquots of t 
0.1 ml 30% sucrose solution co 
trifuge tubes and centrifuged at 
The radioactivity in both the platelet pellet and the superna- 
tant fluid was then determined and the total number of 
molecules ofbound iodine-125-783 was calculated from the 
antibody added, the percent of radioactivity in the pellet and 
the platelet count. The number of glycoprotein IIblIIIa 
receptors blocked by in vivo infusion of unlabeled 7E3- 
F(ab’)Z was defined as the reduction in the number of 
iodine-l25-7E3 molecules that could bind per platelet after 
the infusion. 
Samples for rt-PA and fibrinogen dete 
collected in 0.01 M of citrate and aprotinin 
inhibitor units/ml, Sigma Chemical) solution. 
measured by the coagulation assay of Clauss (27) as 
modified by Vermy~e~ t al. (2 his assay is insensitive to
heparin in plasma concentrati f up to 10 U/ml (29). The 
rt-PA antigen was measured by enzyme-linked immunosor- 
bent assay (ELISAl as described elsewhere (30). Platelet 
aggregation with 1 111 
arachidonic acid (0.5 (31) or with 55 ~1 adenosine 
diphosphate (ADPl (100 $0 (32) per 450 ~1 platelet-rich 
plasma was performed as described elsewhere. 
Template bleeding times were performed on the shaved 
left medial foreleg using a spring-loaded blade device (Sur- 
gicutt International Technidyne). 
Pathologic e~rniRa~~o~. At the end of the experiment, the 
dogs were killed with an overdose of pentobarbital. The 
heart was removed, recanalized arteries were perfusion fixed 
in situ (33) and the whole heart was fixed in a 5% formalde- 
hyde solution. The thrombosed, stenotic and poststenotic 
segments of the left anterior descending coronary artery 
were then removed intact, embedded inparaffin blocks and 
sectioned longitudinally. Longitudinal sections were stained 
with hematoxylin-eosin and examined microscopically for 
the presence of intraluminal ormural thrombi. The relative 
amount of platelets and red blood cells in the thrombus was 
evaluated. 
Statistical analysis. Values are reported as mean values + 
SD. The significance of differences between groups was 
determined with Student’s t test for paired or unpaired 
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CR = cyclic reflow: PO = persistent odusinn: PP = persislenl pilteiKy: I< 
sis of variance w 
~ist~i~~t~~~ of the 
‘limetmin) 
represents panial reflow. Other symbols as in Figure 1. 
-10 a 20 40 6,O 60 100 120 
Timefminb 
-10 0 20 40 60 66 100 120 
L * 
718 YASUDA ET AL. 
SACC Vol. 16. No. 3 
ANTIPLATELET AGENTS AND THROMBOLYSIS September 1990:714=X! 
Table 2. Effect of Aspirin. Argatroban and 7E3-F(ab’I2 on Template Bleeding Time Induced With 
Recombinant Tissue-Type Plasminogen Activator WPA) 
20 Min After Min After 
First rt-PA Last &PA 
Experimental Group No. Before Elolus Bolus End 
I: aspirin 6 3.8 k 0.9 5.3 ? 0.5 5.0 r 0.9 5.0 + 0.9 
II: Argatroban 5 3.8 f 0.8 9.4 + I I 5.2 of: 1.3 5.2 + 1.0 
III: aspirin + Argatrobau 5 4.2 k I.1 I?? II IO z! 3 14 f 9.2 
IV: 7E3-Flab’)2 5 5t3 27 + 8 - 2b f 9 
Data are mean values 2 SD: resuks >30 min are given a 30 min value for calculation of the mean value a SD. 
five dogs (Fig. 2. Dogs I. 2. 4 and 5), with a mean time to 
recanalization of 23 rt 14 min (median 28, range 7 to 120). In 
three of these four dogs (Dogs 2, 4 and 5), the artery 
reoccluded within II Z!Z 13 min and demonstrated cyclic 
changes throughout the experiment. whereas in one dog 
(Dog I) it remained patent. The median number of rt-PA 
bolus injections was two, with a range of one to four. 
Group 111, treated with aspirin and Argatrobnn in com- 
bination with rt-PA, showed recanalization in all six dogs. 
with an average time to reflow ot 24 2 I I min. (median 2 I. 
range I4 to 39) (Table I). Reocclusion occurred in one dog 
(Dog 5) within I3 min, whereas persistent patency was 
observed in the other four. The median number of rt-PA 
bolus injections was two, with a range of one to four. in 
Grollp IV treated with 7iSF(nb’)2 and rt-PA, recanalization 
was achieved in four of five dogs, with a time to reflow of 
27 k I7 min (median 33, range 9 to 120). Reocclusion was 
observed in one dog (Dog I) and cyclic reflow in another 
(Dog 41, with a time to reocclusion of I I + 9 min. whereas 
the other two dogs (Dogs 3 and 5) showed persistent pa- 
tency. The median number of rt-PA bolus injections was 
three (range one to four). 
Several significant differences in coronnry artery patency 
were obsewed with the various infision protocols. A Kruskal- 
Wallis analysis of all experiments with aspirin, Argatroban and 
a combination of the two. with patency status ordered in the 
sequence of persistent occlusion, reocclusion. cyclic reflow 
and persistent patency, yielded a p value of 0.036. Comparison 
of Argatroban with aspirin resulted in a p value of 0.18; 
comparison of the combination of aspirin and Argatroban with 
aspirin showed p = 0.008 and that of Argatroban plus aspirin 
versus Argatroban p = 0.064. Analysis of the patency status of 
the combination of aspirin and Argatroban versus the pooled 
data of either agent alone resulted in a p value of 0. 
Persistent patency occurred more frequently with the combi- 
nation of aspirin and Argatroban than with either agent alone 
(4 of 5 versus I of II, p = 0.013 by Fisher’s exact test). 
KU&Wallis analysis of the patency data obtained with 
7E3-W.02 (Group IV) versus the combined Groups I and II 
treated with either aspirin or Argatroban yielded p = NS, 
whereas comparison with Group III treated with the combina- 
tion resulted in p = NS. 
Wherl the dogs were categorized by time to 
-40 min. two of six dogs in the aspirin g 
the Argatroban group and five of five 
group fell into the category of ~40 min ( 
ison of the results in the aspirin group 
from the Argatroban groups yielded 
p value obtained when the number of 
ategorized into four or fewer than four. 
mostatic a~a~y§~. Before administration of the study 
agent, the activated partial thromboplastin tim 
in all animals. Serial template bleeding times w 
in all dogs and the results are summarized in Ta 
in combination with rt-PA prolonged the 
slightly but significantly from 3.8 2 0.9 to 5.3 
0.03). Argatroban plus &PA induced prolongation of the 
d Argatroban) were co 
was significantly prolonged from 4.2 rt: I. I to I2 + I I min 
(p = 0.04) and this prolongation persisted throughout the 
experiment. When 7E3- (ab’)2 was combined with rt-PA, 
the bleeding time was prolonged from 5 2 3 to 27 + 8 min 
(p = 0.0004). which persisted throughout the experiment. 
Table 3 smmarizes the results of plntelet firnction tests. 
Platelet counts did not change markedly in any of the 
experimental groups. Epinephrinelarachidonic acid aggrega- 
tion was totally abolished in the groups receiving aspirin 
(data not shown), whereas ADP-induced platelet aggregation 
was abolished in the group receiving 7E3-F(ab’)2. Injection 
of 7E3-F(ab’12 produced >75% blocking of glycoprotein 
IIblllla receptors (81 + 13% at 30 min and 76 2 22% at the 
end of the experiment) (data not shown). 
Table 3 cdso summarizes the results of activated psrtiol 
thrombopkastirl nud thrombbt times. Aspirin in combination 
with rt-PA did not affect the activated partial thromboPiasti~ 
or thrombin times before administration of n-PA. whereas a 
moderate prolongation of the results of both assays was 
observed at the end of the experiment. This could be 
ascribed to fibrinogen depletion in two of the animals given 
four bolus injections of &PA. Argatroban at a dose of 200 
&kg per min for 60 min prolonged the activated partial 
thromboplastin time from I3 + I to IO + 28 s and the 
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w4atic Variables 
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Platelet Count 
tx 10’/rnrnlb 
‘Grou No. Pre Baseline efore rt-PA 
*After protamine sulfate injection: *after neutralization of circukiling heparin with protamine snlfale. Ma arc meat1 vaEucs + SD. r&IDA : ~~~~i~b~~~~~~~ 
tissue-type plasminogen activator: ‘l’% = percent change in lighr Iranbmis~ion. 
decreased to 0.72 2 
II: Argatroban 
111: aspirin t Argalrobdn 
5 PA 
6 QT. ER 
I 
2 
3 
4 
5 
bolus i~~ec~io~s were gi 
). The extent of arteria 
occlusive ~brombas. 
rich or mixed with interlaced platelet-rich and erylhrocyte- cumpoGtion is graded as: EN = erythrocyte rich: MPE = mixed with 
rich thrombus. interlaced platelet-rich and erythrocyte-rich thrombus: PK = phlclel rich. 
Ta esults of Pathologic Analysis of ‘~~~~~b~sed Left 
Arterial ~~sse~d~~~ Coronary Arteries 
Expcrimcntal Group 
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Figure 3. Light microphotographs of thrombosed segments of 
the left anterior descending coronary artery after thrombolysis 
with recombinant tissue-type plasminogen activator in associa- 
tion with administration of aspirin and Argatroban (A and Bl or 
7E3-F(ab’)2 (C!). A, A recanalized segment without evidence of 
mural thrombus. B, A platelet-rich mural thrombus (PRMT) in a 
successfully reperfused segment. C, Occlusive red blood cell clot 
(RCC) in the lumen of a segment that had a brief period of partial 
reflow followed by reocclusion. The media (MI reveals varying 
degrees of injury with intramural hemorrhage. in A and B. 
leukocytes (arrows) are present on the-de-wndothelialized intimal 
surfaces and the media. (Hematoxylin. :osin: original magnifica- 
tion x20. reduced by 27%) 
Thrombolytic therapy with recombinant tissue-type las- 
minogen activator @t-PA), one of the most potent agents for 
coronary artery recanalization in patients with acute myo- 
cardial infarction (35). still suffers from significant shortcom- 
ings. When rt-PA is used alone or in combination with 
heparin anticoagulation, coronary reocclusion and unstable 
ischemic events occur in 5% to 30% of patients and a few 
patients remain at risk for serious bleeding (36). 
Role of platelets in coronary thrombosis and thrombolysis. 
Platelets appear to play a central role in the current limita- 
tions of thrombolytic therapy. Coronary artery thrombosis is 
initiated by platelet activation and aggregation at the site of 
ruptured atherosclerotic plaque (37-39). The mechanism of 
platelet-mediated thrombosis i complex, involving platelet 
adhesion and aggregation, as well as activation of the coag- 
ulation system by the exposed subendothelial structures. In
both animal models (25) and patients (6). treatment with 
aspirin in combination with heparin is not uniformly effective 
in preventing thrombus formation at the site of vascular 
injury. Two alternative approaches have been successful in
preventing reocclusion after thrombolysis with rt-PA, 
namely, maintenance rt-PA infusion (12) or the use of a 
potent antiplatelet glycoprotein IlbllIIa antibody (19). How- 
ever, both agents increase the bleeding time and increase the 
risk of bleeding (19.40). 
Recent studies by us (23,241 and others (21,22,41) have 
indicated that selective thrombin inhibitors may be effective 
in the prevention of platelet-mediated arterial thrombosis. 
Therefore, we sought to determine whether acceleration of 
thrombolysis and prevention of reocclusion require extensive 
inhibition of platelet aggregation, such as with the antiplatelet 
glycoprotein Ilb/lIIa 7E3 antibody (19) or combined thrombox- 
ane AZ and serotonin Sz receptor antagonists (18). or whether 
it is possible to achieve comparable efficacy with the use of a 
potent but short-lived synthetic thrombin inhibitor. 
Interpretation of the resuSts of I 
a canine model of coronary artery thrombosis with superim- 
posed high grade stenosis, which has many anatomic simi- 
larities to the coronary artery occlusion in patients with 
study drugs. 
Intravenous bohrs injection of 17 mglkg Astoria c0M- 
leeding time. This observation was unexpect 
technique because e effect of the g~ycoprotein llb/llla 
antibody on the ble ng time in the present study was very 
similar to that obse d in our previous study (19). Clearly, 
the variable response of rent administration schemes of 
r-t-PA in aspirin-treated warrants further investigation 
because it might result in a therapeutic regi 
reduced bleeding tendency in human patients. 
Intravenous bolus injection of aspirin did not markedly 
potentiate the eficacy of &PA in coronary artery thrombol- 
ysis as revealed by both our present results and the results of 
our previous study (25). abort-term infusion of Argatroban 
in a dose that prolonged the activated partial thro 
time from approximately 15 to 85 s accelerated thrombolysis 
compared with the group receiving aspirin alone, whereas 
the combination of Agatroban an 
elusion relative to the groups treat 
In the grotips receiving Argatroban, aspirin and Argatroban 
or 7E3-F(ab’)2, a significant decrease in hematocrit was 
observed, but not in the aspirin alone group. Although 
hemodilution might have contributed to a reduced tendency 
tn a ca 
of reocclusion was not seen. 
result in better e 
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